SANXING(SH:601567)2018-10-30 16:00Financial Performance - Operating revenue for the first nine months rose by 21.35% to CNY 4.21 billion year-on-year[6] - Net profit attributable to shareholders decreased by 0.87% to CNY 415.25 million compared to the same period last year[6] - Total operating revenue for the third quarter reached ¥1,623,585,269.04, an increase of 10.8% compared to ¥1,464,995,478.08 in the same period last year[27] - Net profit for the third quarter was ¥209,028,691.91, representing a 9.4% increase from ¥190,770,604.44 in the previous year[29] - The company reported a total profit of ¥262,521,253.30 for the third quarter, up 8.2% from ¥242,735,981.73 year-on-year[29] Cash Flow - Net cash flow from operating activities dropped significantly by 74.27% to CNY 66.54 million[6] - Cash inflow from operating activities totaled ¥3,145,841,493.17, down 56.5% from ¥7,233,716,941.21 in the same period last year[39] - Cash outflow from operating activities decreased to ¥1,886,699,033.81, compared to ¥7,885,027,580.05 in the previous year, reflecting a reduction of approximately 76%[39] - Cash inflow from investment activities was ¥12,456,509.85, compared to ¥7,213,551.00 in the previous year, showing an increase of 73%[39] - Cash outflow from financing activities totaled ¥6.56 billion, compared to ¥3.86 billion in the same period last year, indicating a significant increase in financing activities[37] Assets and Liabilities - Total assets increased by 20.02% to CNY 15.25 billion compared to the end of the previous year[6] - The total current assets reached RMB 7,276,987,566.51, up from RMB 5,587,073,609.83 in the previous period[20] - Current liabilities rose to ¥5,292,964,618.81, compared to ¥3,923,184,164.46, reflecting an increase of about 35.0%[21] - Non-current liabilities increased to ¥2,345,342,590.99 from ¥1,202,563,575.32, marking a growth of approximately 95.0%[21] - The total liabilities reached ¥7,638,307,209.80, compared to ¥5,125,747,739.78, marking an increase of approximately 49.0%[21] Shareholder Information - The total number of shareholders reached 25,804 by the end of the reporting period[10] - The largest shareholder, Aux Group Co., Ltd., holds 32.08% of the shares[10] - The company repurchased a total of 9,000,800 shares, representing 0.631% of the total share capital, with an average price range of RMB 6.77 to RMB 7.30 per share[15] - The company has implemented a share repurchase plan to enhance market confidence and support the stock price[16] Expenses - Management expenses rose by 73.24% to RMB 353,246,470.22, primarily due to increased medical investments and stock incentive costs[14] - Research and development expenses for the third quarter were ¥63,495,197.90, an increase of 17.3% compared to ¥53,752,014.83 in the same period last year[29] - Sales expenses for the third quarter were ¥111,787,054.09, a decrease of 10.6% from ¥125,101,886.37 in the previous year[27] Other Financial Metrics - The weighted average return on equity decreased by 0.7 percentage points to 5.23%[7] - Basic and diluted earnings per share both decreased by 3.33% to CNY 0.29[7] - The gross profit margin for the third quarter was approximately 7.7%, compared to 10.5% in the same period last year, indicating a decline in profitability[27] - The company's retained earnings decreased to ¥708,328,121.22 from ¥1,011,814,317.61, a decline of about 30.0%[25] - Non-recurring gains and losses totaled CNY 10.50 million for the current period[9] Future Outlook - The company has not disclosed any new product developments or market expansion strategies in this report[5] - The company plans to continue expanding its market presence and invest in new product development to drive future growth[29]